Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer

BACKGROUND: Selenite is a radiosensitizer and inhibitor of androgen receptor expression and function. In a phase I study (NCT02184533) in 15 subjects with metastatic cancer receiving daily oral sodium selenite with palliative radiation therapy, disease stabilization was observed, as evidenced by tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayachandran, Priya, Knox, Susan J., Garcia-Cremades, Maria, Savić, Radojka M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206290/
https://www.ncbi.nlm.nih.gov/pubmed/33866531
http://dx.doi.org/10.1007/s40268-021-00340-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206290/
https://www.ncbi.nlm.nih.gov/pubmed/33866531
http://dx.doi.org/10.1007/s40268-021-00340-9

Ejemplares similares